NCT04901702 2026-04-13
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
Clinical Trials
17 trialsNCT03964532 2026-04-09
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
Phase 1/2 Active not recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT04019327 2025-12-15
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT05035745 2025-07-25
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
Phase 1/2 Recruiting
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03911973 2024-06-07
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT05319249 2024-04-05
NAKIP-AML
German Cancer Research Center
Phase 1/2 Not yet recruiting
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT03875313 2022-02-17
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT03637491 2022-01-26
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT04052204 2021-10-14
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT02116777 2021-03-26
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01989546 2021-02-23
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed